|
Born in
Hong Kong, Sin Hang Lee, M.D., a
practicing pathologist in New Haven, Connecticut, graduated from Wuhan
Medical College, China, in 1956 and is qualified to practice medicine in the
United States, Canada and the United Kingdom. He is certified as a medical specialist
in pathology by the American Board of Pathology and by the Royal College of
Physicians and Surgeons of Canada. He obtained the F.R.C.P.(C) degree in
1966. Dr. Lee's postgraduate training and academic experiences took place at Sichuan Medical College, University of Hong Kong, New York Hospital-Cornell Medical Center, Memorial Hospital for Cancer and Allied Diseases, McGill University and Yale University, summarized in the Marquis Who's Who in the World, 7th Edition (1984-1985) and in Who's Who in Frontiers of Science and Technology, 2nd Edition (1985). Dr. Lee has been practicing pathology in New Haven, Connecticut, since 1971 with past and current affiliations listed in the 2003 edition of Marquis Who's Who in America. Dr. Lee's research interests range from cell biology to cancer. He and Dr. Timothy Ts'o first reported that lung cancer is a leading malignant tumor among the Chinese living in Hong Kong in the British Journal of Cancer (Vol. 17, pp. 37-40, 1963). In contrast to the data reported by others, adenocarcinoma, not squamous cell carcinoma, was found to be the most prevalent type of lung cancer, especially in women. This observation has since been confirmed by other pathologists around the world. Dr. Lee patented the first FDA-approved histochemical estrogen receptor assay for breast cancers based on his work published in Cancer (Vol. 44, pages 1-12, 1979). This assay identifies human breast cancers that may respond to hormonal manipulation or tamoxifen treatment. Dr. Lee has also patented the most specific FDA-approved method for the serologic diagnosis of Mycoplasma pneumoniae infection. Dr. Lee's 2007 research concerns human papillomavirus (HPV) genotyping by DNA sequencing for monitoring persistent HPV infections which may induce cervical cancer in women and for evaluation of prevention strategy for the individual patients to be immunized with type-specific HPV vaccines. Dr. Lee has petitioned the FDA to officially down-classify the HPV test from a cancer test to a virology test, so that small innovative companies can introduce their more accurate new biotechnology tests to benefit consumers. |
![]()
Dr. Lee presenting a
scientific case report on the different uses of green tea at the 5th
Annual A Chef's Delight Food and Wine Tasting Festival organized by the
Wa Sung Charity Fund and the American Cancer Society (Oakland, CA, branch).
|
www.teaforhealth.com
1-866-DRLEE'STea (375-3378)
Fleminger, Inc. •
160 Hawley Lane, Suite 205 •
Trumbull, CT 06611
© 2003-2004. TeaForHealth.